STAT+: Pharmalittle: Investors reject proposals for Covid vaccine makers to share know-how; CMS head says Alzheimer’s drug decision is rare
CMS head Chiquita Brooks-LaSure says the agency expects to keep covering drugs that the FDA approves through its fast-track accelerated approval pathway, despite its recent decision on Biogen's Aduhelm.
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured
